How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about sotorasib

Marketing authorisation indication

2.1

Sotorasib (Lumykras, Amgen) is indicated for 'the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy'.

Dosage in the marketing authorisation

Price

2.3

The list price of sotorasib is £6,907.35 for a 30-day supply of 120 tablets, each containing 240 mg (excluding VAT; BNF online accessed February 2026).

2.4

The company has a commercial arrangement, which would have applied if sotorasib had been recommended.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Amgen will be included here when guidance is published.